Literature DB >> 21438754

Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes.

Juan Carlos Yugar-Toledo1, José Fernando Vilela Martin, José Eduardo Krieger, Alexandre C Pereira, Caroline Demacq, Otávio Rizzi Coelho, Eduardo Pimenta, David A Calhoun, Heitor Moreno Júnior.   

Abstract

Resistant hypertension, a complex multifactorial hypertensive disease, is triggered by genetic and environmental factors and involves multiple physiological pathways. Single genetic variants may not reveal significant associations with resistant hypertension because their effects may be dependent on gene-gene or gene-environment interactions. We examined the interaction of angiotensin I-converting enzyme (ACE), angiotensinogen (AGT), and endothelial nitric oxide synthase (NOS3) polymorphisms with environmental factors (gender, age, body mass index, glycemia, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate, and urinary sodium excretion) in 70 resistant, 80 well-controlled hypertensive patients, and 70 normotensive controls. All subjects were genotyped for ACE insertion/deletion (rs1799752); AGT M235T (rs699), and NOS3 Glu298Asp (rs 1799983). Multifactorial associations were tested using two statistical methods: the traditional parametric method (adjusted logistic regression analysis) and gene-gene and gene-environment interactions evaluated by multifactor dimensionality reduction analyses. While adjusted logistic regression found no significant association between the studied polymorphisms and controlled or resistant hypertension, the multifactor dimensionality reduction analyses showed that carriers of the AGT 235T allele were at increased risk for resistant hypertension, especially if they were older than 50 years. The AGT 235T allele constituted an independent risk factor for resistant hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21438754     DOI: 10.1089/dna.2010.1156

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  17 in total

1.  Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.

Authors:  Marguerite R Irvin; Daichi Shimbo; Devin M Mann; Kristi Reynolds; Marie Krousel-Wood; Nita A Limdi; Daniel T Lackland; David A Calhoun; Suzanne Oparil; Paul Muntner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-08-03       Impact factor: 3.738

Review 2.  Resistant hypertension: concepts and approach to management.

Authors:  Gary E Sander; Thomas D Giles
Journal:  Curr Hypertens Rep       Date:  2011-10       Impact factor: 5.369

Review 3.  Resistant Hypertension: Mechanisms and Treatment.

Authors:  Andrew Y Hwang; Eric Dietrich; Carl J Pepine; Steven M Smith
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

Review 4.  An update on the pharmacogenetics of treating hypertension.

Authors:  V Fontana; M R Luizon; V C Sandrim
Journal:  J Hum Hypertens       Date:  2014-08-28       Impact factor: 3.012

Review 5.  Genetics of resistant hypertension: a novel pharmacogenomics phenotype.

Authors:  Nihal El Rouby; Rhonda M Cooper-DeHoff
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

Review 6.  Application of omics in hypertension and resistant hypertension.

Authors:  Jiuqi Guo; Xiaofan Guo; Yingxian Sun; Zhao Li; Pengyu Jia
Journal:  Hypertens Res       Date:  2022-03-09       Impact factor: 3.872

7.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

8.  Brazilian Position Statement on Resistant Hypertension - 2020.

Authors:  Juan Carlos Yugar-Toledo; Heitor Moreno Júnior; Miguel Gus; Guido Bernardo Aranha Rosito; Luiz César Nazário Scala; Elizabeth Silaid Muxfeldt; Alexandre Alessi; Andrea Araújo Brandão; Osni Moreira Filho; Audes Diógenes de Magalhães Feitosa; Oswaldo Passarelli Júnior; Dilma do Socorro Moraes de Souza; Celso Amodeo; Weimar Kunz Sebba Barroso; Marco Antônio Mota Gomes; Annelise Machado Gomes de Paiva; Eduardo Costa Duarte Barbosa; Roberto Dischinger Miranda; José Fernando Vilela-Martin; Wilson Nadruz Júnior; Cibele Isaac Saad Rodrigues; Luciano Ferreira Drager; Luiz Aparecido Bortolotto; Fernanda Marciano Consolim-Colombo; Márcio Gonçalves de Sousa; Flávio Antonio de Oliveira Borelli; Sérgio Emanuel Kaiser; Gil Fernando Salles; Maria de Fátima de Azevedo; Lucélia Batista Neves Cunha Magalhães; Rui Manoel Dos Santos Póvoa; Marcus Vinícius Bolívar Malachias; Armando da Rocha Nogueira; Paulo César Brandão Veiga Jardim; Thiago de Souza Veiga Jardim
Journal:  Arq Bras Cardiol       Date:  2020 May-Jun       Impact factor: 2.000

Review 9.  Genetics of Resistant Hypertension: the Missing Heritability and Opportunities.

Authors:  Samantha K Teixeira; Alexandre C Pereira; Jose E Krieger
Journal:  Curr Hypertens Rep       Date:  2018-05-19       Impact factor: 5.369

Review 10.  Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?

Authors:  J C Yugar-Toledo; V Brunelli; J F Vilela-Martin; A Fattori; H Moreno
Journal:  Curr Hypertens Rep       Date:  2018-03-27       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.